{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:43:34Z","timestamp":1792028614385,"version":"4.4.0"},"reference-count":87,"publisher":"National Institute for Health and Care Research","issue":"52","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["12\/35\/54"],"award-info":[{"award-number":["12\/35\/54"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Prostate cancer (PCa) is the most common cancer in men in the UK. Patients with intermediate-risk, clinically localised disease are offered radical treatments such as surgery or radiotherapy, which can result in severe side effects. A number of alternative partial ablation (PA) technologies that may reduce treatment burden are available; however the comparative effectiveness of these techniques has never been evaluated in a randomised controlled trial (RCT).<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To assess the feasibility of a RCT of PA using high-intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) for intermediate-risk PCa and to test and optimise methods of data capture.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n We carried out a prospective, multicentre, open-label feasibility study to inform the design and conduct of a future RCT, involving a QuinteT Recruitment Intervention (QRI) to understand barriers to participation.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Five NHS hospitals in England.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Men with unilateral, intermediate-risk, clinically localised PCa.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Radical prostatectomy compared with HIFU.<\/jats:p>\n <\/jats:sec>\n \n Primary outcome measure<\/jats:title>\n The randomisation of 80 men.<\/jats:p>\n <\/jats:sec>\n \n Secondary outcome measures<\/jats:title>\n Findings of the QRI and assessment of data capture methods.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Eighty-seven patients consented to participate by 31 March 2017 and 82 men were randomised by 4 May 2017 (41 men to the RP arm and 41 to the HIFU arm). The QRI was conducted in two iterative phases: phase I identified a number of barriers to recruitment, including organisational challenges, lack of recruiter equipoise and difficulties communicating with patients about the study, and phase II comprised the development and delivery of tailored strategies to optimise recruitment, including group training, individual feedback and \u2018tips\u2019 documents. At the time of data extraction, on 10 October 2017, treatment data were available for 71 patients. Patient characteristics were similar at baseline and the rate of return of all clinical case report forms (CRFs) was 95%; the return rate of the patient-reported outcome measures (PROMs) questionnaire pack was 90.5%. Centres with specific long-standing expertise in offering HIFU as a routine NHS treatment option had lower recruitment rates (Basingstoke and Southampton) \u2013 with University College Hospital failing to enrol any participants \u2013 than centres offering HIFU in the trial context only.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Randomisation of men to a RCT comparing PA with radical treatments of the prostate is feasible. The QRI provided insights into the complexities of recruiting to this surgical trial and has highlighted a number of key lessons that are likely to be important if the study progresses to a main trial. A full RCT comparing clinical effectiveness, cost-effectiveness and quality-of-life outcomes between radical treatments and PA is now warranted.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n Men recruited to the feasibility study will be followed up for 36 months in accordance with the protocol. We will design a full RCT, taking into account the lessons learnt from this study. CRFs will be streamlined, and the length and frequency of PROMs and resource use diaries will be reviewed to reduce the burden on patients and research nurses and to optimise data completeness.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n Current Controlled Trials ISRCTN99760303.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment<\/jats:italic>; Vol. 22, No. 52. See the NIHR Journals Library website for further project information.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta22520","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T10:24:08Z","timestamp":1538130248000},"page":"1-96","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":56,"title":["Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT"],"prefix":"10.3310","volume":"22","clinical-trial-number":[{"clinical-trial-number":"isrctn99760303","registry":"10.18810\/isrctn","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2627-2154","authenticated-orcid":true,"given":"Freddie C","family":"Hamdy","sequence":"first","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8143-9549","authenticated-orcid":true,"given":"Daisy","family":"Elliott","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8095-2738","authenticated-orcid":true,"given":"Steffi","family":"le Conte","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6632-7215","authenticated-orcid":true,"given":"Lucy C","family":"Davies","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6100-7618","authenticated-orcid":true,"given":"Rich\u00e9al M","family":"Burns","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9433-7779","authenticated-orcid":true,"given":"Claire","family":"Thomson","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4440-574X","authenticated-orcid":true,"given":"Richard","family":"Gray","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7493-1850","authenticated-orcid":true,"given":"Jane","family":"Wolstenholme","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6488-5472","authenticated-orcid":true,"given":"Jenny L","family":"Donovan","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK"},{"name":"National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care West at University Hospitals Bristol NHS Foundation Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0607-0563","authenticated-orcid":true,"given":"Ray","family":"Fitzpatrick","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4905-8233","authenticated-orcid":true,"given":"Clare","family":"Verrill","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5121-3917","authenticated-orcid":true,"given":"Fergus","family":"Gleeson","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2516-8435","authenticated-orcid":true,"given":"Surjeet","family":"Singh","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9086-3592","authenticated-orcid":true,"given":"Derek","family":"Rosario","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2787-8828","authenticated-orcid":true,"given":"James WF","family":"Catto","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2151-6893","authenticated-orcid":true,"given":"Simon","family":"Brewster","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6373-3613","authenticated-orcid":true,"given":"Tim","family":"Dudderidge","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-1694","authenticated-orcid":true,"given":"Richard","family":"Hindley","sequence":"additional","affiliation":[{"name":"Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5619-261X","authenticated-orcid":true,"given":"Amr","family":"Emara","sequence":"additional","affiliation":[{"name":"Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1398-3961","authenticated-orcid":true,"given":"Prasanna","family":"Sooriakumaran","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-6723","authenticated-orcid":true,"given":"Hashim U","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Surgery and Cancer, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-1840","authenticated-orcid":true,"given":"Tom A","family":"Leslie","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2018,9]]},"reference":[{"key":"key20180927125753929_ref1-bib1","volume-title":"Prostate Cancer Statistics Table 2014","author":"Cancer Research UK"},{"key":"key20180927125753929_ref1-bib2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"key20180927125753929_ref1-bib3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00345-008-0330-8","article-title":"Active surveillance for prostate cancer: trials and tribulations","volume":"26","author":"Klotz","year":"2008","journal-title":"World J Urol"},{"key":"key20180927125753929_ref1-bib4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/PPO.0b013e318156ff65","article-title":"Active surveillance with selective radical treatment for localized prostate cancer","volume":"13","author":"van As","year":"2007","journal-title":"Cancer J"},{"key":"key20180927125753929_ref1-bib5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJM199401273300403","article-title":"Results of conservative management of clinically localized prostate cancer","volume":"330","author":"Chodak","year":"1994","journal-title":"N Engl J Med"},{"key":"key20180927125753929_ref1-bib6","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1002\/cncr.24446","article-title":"Anxiety and distress during active surveillance for early prostate cancer","volume":"115","author":"van den Bergh","year":"2009","journal-title":"Cancer"},{"key":"key20180927125753929_ref1-bib7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3816\/CGC.2003.n.017","article-title":"Active surveillance with selective delayed intervention: a biologically nuanced approach to favorable-risk prostate cancer","volume":"2","author":"Klotz","year":"2003","journal-title":"Clin Prostate Cancer"},{"key":"key20180927125753929_ref1-bib8","volume-title":"Major Resections by Cancer Site, in England; 2006 to 2010","author":"Cancer Research UK","year":"2015"},{"key":"key20180927125753929_ref1-bib9","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"key":"key20180927125753929_ref1-bib10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jama.292.7.821","article-title":"6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial","volume":"292","author":"D\u2019Amico","year":"2004","journal-title":"JAMA"},{"key":"key20180927125753929_ref1-bib11","doi-asserted-by":"publisher","first-page":"8176","DOI":"10.1200\/JCO.2005.03.4629","article-title":"Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions","volume":"23","author":"Speight","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180927125753929_ref1-bib12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"key20180927125753929_ref1-bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","article-title":"EAU guidelines on prostate cancer. part 1: screening, diagnosis, and treatment of clinically localised disease","volume":"59","author":"Heidenreich","year":"2011","journal-title":"Eur Urol"},{"key":"key20180927125753929_ref1-bib14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0360-3016(03)00784-3","article-title":"Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy \u2265\u200972 Gy, permanent seed implantation, or combined seeds\/external beam radiotherapy for stage T1\u2013T2 prostate cancer","volume":"58","author":"Kupelian","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20180927125753929_ref1-bib15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jama.2017.1703","article-title":"Patient-reported outcomes following treatment for localized prostate cancer: helping decision making for patients and their physicians","volume":"317","author":"Hamdy","year":"2017","journal-title":"JAMA"},{"key":"key20180927125753929_ref1-bib16","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"key":"key20180927125753929_ref1-bib17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/jjco\/hym173","article-title":"Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer","volume":"38","author":"Muto","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"key20180927125753929_ref1-bib18","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S1569-9056(09)60842-3","article-title":"High intensity focused ultrasound (HIFU) hemiablation trial in localised unilateral prostate cancer: interim results","volume":"8","author":"Ahmed","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"key20180927125753929_ref1-bib19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1470-2045(12)70121-3","article-title":"Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study","volume":"13","author":"Ahmed","year":"2012","journal-title":"Lancet Oncol"},{"key":"key20180927125753929_ref1-bib20","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1158\/1078-0432.CCR-16-2745","article-title":"Bombesin antagonist-based radiotherapy of prostate cancer combined with WST-11 vascular targeted photodynamic therapy","volume":"23","author":"Kim","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20180927125753929_ref1-bib21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.eururo.2010.09.009","article-title":"Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer","volume":"58","author":"Warmuth","year":"2010","journal-title":"Eur Urol"},{"key":"key20180927125753929_ref1-bib22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.clon.2010.09.002","article-title":"High-intensity focused ultrasound for prostate cancer: a systematic review","volume":"23","author":"Lukka","year":"2011","journal-title":"Clin Oncol"},{"key":"key20180927125753929_ref1-bib23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.euf.2015.04.006","article-title":"Systematic review of the efficacy and safety of high-intensity focussed ultrasound for localised prostate cancer","volume":"1","author":"Veereman","year":"2015","journal-title":"Eur Urol Focus"},{"key":"key20180927125753929_ref1-bib24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1159\/000441600","article-title":"Role of focal therapy with high-intensity focused ultrasound in the management of clinically localized prostate cancer","volume":"38","author":"Kuru","year":"2015","journal-title":"Oncol Res Treat"},{"key":"key20180927125753929_ref1-bib25","doi-asserted-by":"publisher","first-page":"CD005010","DOI":"10.1002\/14651858.CD005010.pub2","article-title":"Cryotherapy for localised prostate cancer","volume":"3","author":"Shelley","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"key20180927125753929_ref1-bib26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/cncr.24779","article-title":"A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer","volume":"116","author":"Donnelly","year":"2010","journal-title":"Cancer"},{"key":"key20180927125753929_ref1-bib27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1148\/radiol.2441060398","article-title":"Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide","volume":"244","author":"Haider","year":"2007","journal-title":"Radiology"},{"key":"key20180927125753929_ref1-bib28","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.juro.2007.07.036","article-title":"Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response","volume":"178","author":"Trachtenberg","year":"2007","journal-title":"J Urol"},{"key":"key20180927125753929_ref1-bib29","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/j.1464-410X.2008.07753.x","article-title":"Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses","volume":"102","author":"Trachtenberg","year":"2008","journal-title":"BJU Int"},{"key":"key20180927125753929_ref1-bib30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1562\/2004-05-31-RA-182","article-title":"Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and in patients","volume":"81","author":"Weersink","year":"2005","journal-title":"Photochem Photobiol"},{"key":"key20180927125753929_ref1-bib31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S1569-9056(10)60916-5","article-title":"936 TOOKAD\u00ae Soluble (Padeliporfin) second generation targeted photodynamic therapy (VTP) for prostate cancer: safety and feasibility","volume":"9","author":"Arumainayagam","year":"2010","journal-title":"Eur Urol Suppl"},{"key":"key20180927125753929_ref1-bib32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1046\/j.1464-410X.1998.00504.x","article-title":"Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer","volume":"81","author":"Zlotta","year":"1998","journal-title":"Br J Urol"},{"key":"key20180927125753929_ref1-bib33","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S0090-4295(97)00540-2","article-title":"Transperineal radiofrequency interstitial tumor ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination","volume":"50","author":"Djavan","year":"1997","journal-title":"Urology"},{"key":"key20180927125753929_ref1-bib34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1089\/end.2005.19.865","article-title":"Ablation of stage T1\/T2 prostate cancer with permanent interstitial temperature self-regulating rods","volume":"19","author":"Tucker","year":"2005","journal-title":"J Endourol"},{"key":"key20180927125753929_ref1-bib35","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/pros.20242","article-title":"Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer","volume":"65","author":"Shariat","year":"2005","journal-title":"Prostate"},{"key":"key20180927125753929_ref1-bib36","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1259\/0007-1285-66-791-1044","article-title":"Technical note: interstitial laser photocoagulation for the treatment of prostatic cancer","volume":"66","author":"Amin","year":"1993","journal-title":"Br J Radiol"},{"key":"key20180927125753929_ref1-bib37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/153303460700600405","article-title":"Irreversible electroporation: implications for prostate ablation","volume":"6","author":"Onik","year":"2007","journal-title":"Technol Cancer Res Treat"},{"key":"key20180927125753929_ref1-bib38","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1016\/j.juro.2008.08.003","article-title":"Optimal parameters for the destruction of prostate cancer using irreversible electroporation","volume":"180","author":"Rubinsky","year":"2008","journal-title":"J Urol"},{"key":"key20180927125753929_ref1-bib39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12885-016-2332-z","article-title":"Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial","volume":"16","author":"Scheltema","year":"2016","journal-title":"BMC Cancer"},{"issue":"49","key":"key20180927125753929_ref1-bib40","doi-asserted-by":"publisher","DOI":"10.3310\/hta19490","article-title":"Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation","volume":"19","author":"Ramsay","year":"2015","journal-title":"Health Technol Assess"},{"key":"key20180927125753929_ref1-bib41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2016.08.044","article-title":"New and established technology in focal ablation of the prostate: a systematic review","volume":"71","author":"Valerio","year":"2016","journal-title":"Eur Urol"},{"key":"key20180927125753929_ref1-bib42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.urology.2007.07.037","article-title":"Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006","volume":"70","author":"Bostwick","year":"2007","journal-title":"Urology"},{"key":"key20180927125753929_ref1-bib43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1745-6215-7-9","article-title":"What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies","volume":"7","author":"McDonald","year":"2006","journal-title":"Trials"},{"key":"key20180927125753929_ref1-bib44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/1740774516687272","article-title":"Delivering successful randomized controlled trials in surgery: methods to optimize collaboration and study design","volume":"14","author":"Blencowe","year":"2017","journal-title":"Clin Trials"},{"key":"key20180927125753929_ref1-bib45","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1200\/JCO.2007.14.8114","article-title":"Influence of clinical communication on patients\u2019 decision making on participation in clinical trials","volume":"26","author":"Albrecht","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180927125753929_ref1-bib46","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.jclinepi.2014.03.010","article-title":"The intellectual challenges and emotional consequences of equipoise contributed to the fragility of recruitment in six randomized controlled trials","volume":"67","author":"Donovan","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"key20180927125753929_ref1-bib47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1745-6215-15-5","article-title":"Clear obstacles and hidden challenges: understanding recruiter perspectives in six pragmatic randomised controlled trials","volume":"15","author":"Donovan","year":"2014","journal-title":"Trials"},{"key":"key20180927125753929_ref1-bib48","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jclinepi.2016.02.002","article-title":"A new simple six-step model to promote recruitment to RCTs was developed and successfully implemented","volume":"76","author":"Realpe","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"key20180927125753929_ref1-bib49","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/10810730.2013.801537","article-title":"Last resort or roll of the die? Exploring the role of metaphors in cancer clinical trials education among medically underserved populations","volume":"19","author":"Krieger","year":"2014","journal-title":"J Health Commun"},{"key":"key20180927125753929_ref1-bib50","doi-asserted-by":"publisher","first-page":"e000496","DOI":"10.1136\/bmjopen-2011-000496","article-title":"Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review","volume":"2","author":"Fletcher","year":"2012","journal-title":"BMJ Open"},{"key":"key20180927125753929_ref1-bib51","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s13063-015-0908-6","article-title":"A systematic review of training programmes for recruiters to randomised controlled trials","volume":"16","author":"Townsend","year":"2015","journal-title":"Trials"},{"key":"key20180927125753929_ref1-bib52","doi-asserted-by":"publisher","first-page":"e002360","DOI":"10.1136\/bmjopen-2012-002360","article-title":"Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis","volume":"3","author":"Treweek","year":"2013","journal-title":"BMJ Open"},{"key":"key20180927125753929_ref1-bib53","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13063-016-1391-4","article-title":"Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI)","volume":"17","author":"Donovan","year":"2016","journal-title":"Trials"},{"key":"key20180927125753929_ref1-bib54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jclinepi.2008.02.010","article-title":"Development of a complex intervention improved randomization and informed consent in a randomized controlled trial","volume":"62","author":"Donovan","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"key20180927125753929_ref1-bib55","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.eururo.2017.04.036","article-title":"Understanding and improving recruitment to randomised controlled trials: qualitative research approaches","volume":"72","author":"Elliott","year":"2017","journal-title":"Eur Urol"},{"key":"key20180927125753929_ref1-bib56","volume-title":"Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory","author":"Strauss","year":"1998","edition":"2nd edn."},{"key":"key20180927125753929_ref1-bib57","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"key":"key20180927125753929_ref1-bib58","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"key20180927125753929_ref1-bib59","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"key20180927125753929_ref1-bib60","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","article-title":"Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument","volume":"50","author":"Esper","year":"1997","journal-title":"Urology"},{"key":"key20180927125753929_ref1-bib61","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0090-4295(00)00858-X","article-title":"Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","volume":"56","author":"Wei","year":"2000","journal-title":"Urology"},{"key":"key20180927125753929_ref1-bib62","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1002\/cncr.11386","article-title":"The Memorial Anxiety Scale for Prostate Cancer: validation of a new scale to measure anxiety in men with prostate cancer","volume":"97","author":"Roth","year":"2003","journal-title":"Cancer"},{"key":"key20180927125753929_ref1-bib63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10198-013-0502-3","article-title":"The development of new research methods for the valuation of EQ-5D-5L","volume":"14","author":"Devlin","year":"2013","journal-title":"Eur J Health Econ"},{"key":"key20180927125753929_ref1-bib64","volume-title":"Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England","author":"Devlin","year":"2016"},{"issue":"41","key":"key20180927125753929_ref1-bib65","doi-asserted-by":"publisher","DOI":"10.3310\/hta16410","article-title":"Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer","volume":"16","author":"Ramsay","year":"2012","journal-title":"Health Technol Assess"},{"key":"key20180927125753929_ref1-bib66","volume-title":"NHS Reference Costs 2014 to 2015","author":"Department of Health and Social Care","year":"2015"},{"key":"key20180927125753929_ref1-bib67","volume-title":"Dataset for Histopathology Reports for Prostatic Carcinoma","author":"Royal College of Pathologists","year":"2009","edition":"2nd edn."},{"key":"key20180927125753929_ref1-bib68","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"key20180927125753929_ref1-bib69","volume-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2016","edition":"7th edn."},{"key":"key20180927125753929_ref1-bib70","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/jclinpath-2011-200460","article-title":"Prostatic needle biopsies following primary high intensity focused ultrasound (HIFU) therapy for prostatic adenocarcinoma: histopathological features in tumour and non-tumour tissue","volume":"65","author":"Ryan","year":"2012","journal-title":"J Clin Pathol"},{"key":"key20180927125753929_ref1-bib71","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1464-410X.2012.11611.x","article-title":"Prognostic Gleason grade grouping: data based on the modified Gleason scoring system","volume":"111","author":"Pierorazio","year":"2013","journal-title":"BJU Int"},{"key":"key20180927125753929_ref1-bib72","volume-title":"High-intensity Focused Ultrasound for Prostate Cancer. Interventional Procedures Guidance [IPG118]","author":"National Institute for Health and Care Excellence"},{"key":"key20180927125753929_ref1-bib73","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cct.2008.03.003","article-title":"Qualitative research to improve RCT recruitment: issues arising in establishing research collaborations","volume":"29","author":"de Salis","year":"2008","journal-title":"Contemp Clin Trials"},{"key":"key20180927125753929_ref1-bib74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1745-6215-16-3","article-title":"Uncovering the emotional aspects of working on a clinical trial: a qualitative study of the experiences and views of staff involved in a type 1 diabetes trial","volume":"16","author":"Lawton","year":"2015","journal-title":"Trials"},{"key":"key20180927125753929_ref1-bib75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijotn.2015.05.002","article-title":"Understanding involvement in surgical orthopaedic randomized controlled trials: a qualitative study of patient and health professional views and experiences","volume":"20","author":"Horwood","year":"2016","journal-title":"Int J Orthop Trauma Nurs"},{"issue":"10","key":"key20180927125753929_ref1-bib76","doi-asserted-by":"publisher","DOI":"10.3310\/hta20100","article-title":"OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer","volume":"20","author":"Stein","year":"2016","journal-title":"Health Technol Assess"},{"key":"key20180927125753929_ref1-bib77","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/135581960000500307","article-title":"Clinicians\u2019 attitudes to recruitment to randomised trials in cancer care: a qualitative study","volume":"5","author":"Langley","year":"2000","journal-title":"J Health Serv Res Policy"},{"key":"key20180927125753929_ref1-bib78","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13063-016-1323-3","article-title":"Recruiting and consenting into a peripartum trial in an emergency setting: a qualitative study of the experiences and views of women and healthcare professionals","volume":"17","author":"Lawton","year":"2016","journal-title":"Trials"},{"key":"key20180927125753929_ref1-bib79","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.eururo.2015.10.030","article-title":"The effects of focal therapy for prostate cancer on sexual function: a combined analysis of three prospective trials","volume":"69","author":"Yap","year":"2016","journal-title":"Eur Urol"},{"key":"key20180927125753929_ref1-bib80","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12894-017-0198-2","article-title":"Quality of life and functional outcome after infravesical desobstruction and HIFU treatment for localized prostate cancer","volume":"17","author":"Hatiboglu","year":"2017","journal-title":"BMC Urol"},{"key":"key20180927125753929_ref1-bib81","volume-title":"Dataset for Histopathology Reports for Prostatic Carcinoma","author":"Oxley","year":"2016","edition":"3rd edn."},{"key":"key20180927125753929_ref1-bib82","doi-asserted-by":"publisher","first-page":"e1002147","DOI":"10.1371\/journal.pmed.1002147","article-title":"Conveying equipoise during recruitment for clinical trials: qualitative synthesis of clinicians\u2019 practices across six randomised controlled trials","volume":"13","author":"Rooshenas","year":"2016","journal-title":"PLOS Med"},{"key":"key20180927125753929_ref1-bib83","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jclinepi.2016.07.016","article-title":"A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable","volume":"80","author":"Briel","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"key20180927125753929_ref1-bib84","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1745-6215-15-323","article-title":"Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients\u2019 treatment preferences","volume":"15","author":"Mills","year":"2014","journal-title":"Trials"},{"key":"key20180927125753929_ref1-bib85","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"key20180927125753929_ref1-bib86","volume-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2017","edition":"8th edn."},{"key":"key20180927125753929_ref1-bib87","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017","edition":"8th edn."}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta22520\/hta22520.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2003419","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta22520\/hta22520.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2021333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:55:15Z","timestamp":1692114915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta22520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":87,"journal-issue":{"issue":"52","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["10.3310\/hta22520"],"URL":"https:\/\/doi.org\/10.3310\/hta22520","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}